Recent Company News

• 08:18 AM ET May 01, 2026
  

  Biotech IPO market upsized in CY26

• 06:22 PM ET Apr 23, 2026
  

  AgomAb Therapeutics NV reports FY EPS (€143.22) vs year-ago (€107.09) ($10.70, 0.00)

• 07:10 AM ET Mar 26, 2026
  

  Agomab receives U.S. Patent for AGMB-447 ($12.86, 0.00)

• 12:45 PM ET Mar 08, 2026
  

  StreetAccount Sector Summary: Healthcare Monthly Recap - February 2026

• 04:54 PM ET Mar 03, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:42 AM ET Mar 03, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:22 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated outperform at Leerink Partners ($16.21, 0.00)

• 06:04 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated overweight at Morgan Stanley ($16.21, 0.00)

• 06:03 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated overweight at JPMorgan ($16.21, 0.00)

• 02:00 PM ET Feb 09, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 2-Feb